Clinical trial on efficacy and safety of long-term Rebamipide therapy for successful eradication of Helicobacter pylori.

Clinical trial on efficacy and safety of long-term Rebamipide therapy for successful eradication of Helicobacter pylori. - Efficacy of rebamipide for gastritis after eradication of Helicobacter pylori.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002369

Enrollment

250

Registered

2010-01-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who successful eradication therapy of Helicobacter pylori.

Interventions

treatment group receive rebamipide 300mg three times daily for 1 year. control group do not receive rebamipide.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who fills everything the following 1) Helicobacter pylori-positive patient. 2) Patient of 20 years or more 3) Early gastric cancer, planning to have endoscopic treatment. 4) Patient who gives written informed consent

Exclusion criteria

Exclusion criteria: 1) Subjects with malignancy 2) Drug allergy 3) Severe complication 4) take non-steroidal inflammatory drugs 5) H. pylori eradication failure after first and second-line therapy. 6) Cases with unsuitable recognition by doctors

Design outcomes

Primary

Measure	Time frame
Change of histological gastritis	—

Countries

Japan

Contacts

Public ContactTomoari Kamada

Kawasaki Medical School Department of Internal Medicine, division of Gastroenterology

tkamada@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026